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Received March 27, 2013; accepted March 31, 2014AbstractBackground: Kawasaki disease is the leading cause of pediatric acquired cardiac disease in many industrialized countries. The aim of this study
was to estimate the incidence of Kawasaki disease in acute stages in Taiwan, by linking the diagnosis code to medication and comparing the
differences in epidemiological features with those of previous reports that used the diagnosis code alone.
Methods: We searched the National Health Insurance Research Database from 1997 to 2010. For the International Classification of Diseases,
Ninth Revision (ICD-9) set, all inpatients with a main diagnosis of Kawasaki disease (ICD-9, 446.1) were retrieved. For the ICD-9 þ intravenous
immunoglobulin (IVIG) set, Kawasaki disease in acute stages was defined as the disease stages requiring IVIG. The epidemiologic features were
calculated and compared by both methods.
Results: The incidence rates for children under 5 years ranged from 21.5 to 68.5 per 100,000 person-years (average 49.1) for the ICD-9 þ IVIG
set and from 48.5 to 82.8 per 100,000 person-years (average 74.9) for the ICD-9 set. Significant discrepancy in peak season estimation occurred
in summer. The 5-year recurrence rate was 1.1% for the ICD-9 þ IVIG set and 4.5% for the ICD-9 set. The coronary complication rates were
around 7.24% (ICD-9 þ IVIG) and 6.48% (ICD-9).
Conclusion: Discrepancies occurred when different case definitions were used in claims data analysis. Previous reports might have overestimated
the incidence, recurrence rate, and complication rate in older children. The new method might slightly underestimate them. The true incidence
might lie in between.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Kawasaki disease is an acute, self-limited, systemic
vasculitis.1 It is now the leading cause of acquired cardiac
disease in children in many industrialized countries.2e10 ItConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2014.03.009
1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Assmay induce coronary artery abnormalities ranging from tran-
sient ectasia and small aneurysms to giant aneurysms.11e13
Prompt diagnosis and timely administration of intravenous
immunoglobulin (IVIG) are crucial to prevent coronary
complications.1,14e18 Thus, estimating the incidence of Ka-
wasaki disease in acute stages is important for understanding
the disease burden and public health policy making.
Incidences of Kawasaki disease in different countries were
reported previously.3e10,13,19e21 Most of the data were derived
from either claims data analysis or hospital surveys. Few
countries have a Kawasaki disease registry.4 The incidence of
Kawasaki disease in Taiwan has also been reported previously.ociation. All rights reserved.
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Health Insurance (NHI) have been used.6,19,20 However, there
are some discrepancies in the data derived from these two
resources (Table 1).6,19,20 The hospital survey is regarded as
noncomprehensive and subject to double counting when pa-
tients are transferred between hospitals. As the NHI has been
available in Taiwan since 1996 and covers more than 98% of
the population,22,23 epidemiologic data retrieved from its
database are regarded as more reliable and comprehensive.
However, previous reports using claims data from the NHI
focused on admission with a main diagnosis code of Kawasaki
disease. Whether the reason for admission was the acute stages
of this disease or not was not well defined.6,19 This might
somewhat overestimate the disease incidence.
As IVIG therapy is covered by the NHI when an acute
episode of Kawasaki disease is diagnosed, including incom-
plete Kawasaki disease, most patients in Taiwan receive IVIG
in the initial stage of illness. Therefore, Kawasaki disease in
acute stages could possibly be defined by analyzing the use of
IVIG. The aim of this study was to estimate the incidence of
Kawasaki disease in acute stages in Taiwan, by linking the
diagnosis code to medication and comparing the differences in
the epidemiological features with those of previous reports
that used the diagnosis code alone.
2. Methods
This was a retrospective cohort study. Although the NHI of
Taiwan was initiated in 1995, the database for that year was
incomplete. We, therefore, searched the National Health In-
surance Research Database (NHIRD) of Taiwan to collect
patients' medical records from 1997 to 2010. Files of inpatient
expenditure by admission (DD1997eDD2010 files) and de-
tails of inpatient orders (DO1997eDO2010 files) were the
main resources for data analysis.
For the International Classification of Diseases, Ninth
Revision (ICD-9) set, medical records of all inpatients whose
first or second diagnosis was Kawasaki disease (ICD-9, 446.1)
were retrieved. On the other hand, for the ICD-9 þ IVIG set,
in addition to the first or second diagnosis fulfilling the criteria
for Kawasaki disease (ICD-9, 446.1), we further cross-linked
the details of inpatient orders to see if patients were treated
with IVIG. Patients were regarded as having received IVIG
therapy if their inpatient orders included medication whose
anatomical therapeutic classification code was J06BA02.
Coronary aneurysm was identified by any discharge diagnosis,Table 1
Comparison of incidence, recurrence, and coronary artery complication rates
among previous series and this study.
Incidence
rate a
Recurrence
rate (%)
Coronary artery
complication rate (%)
Lue et al20 55 d 25.8
Chang et al19 66 1.3 7.3
Huang et al6 69 1.5 7.2
This study 49 1.1 7.2
a Incidence rate unit: 100,000 children aged under 5 years per year.including ICD-9 414.11. Recurrence was defined as read-
mission of patients with a main diagnosis of Kawasaki disease
in the ICD-9 set, and readmission of patients with a main
diagnosis of Kawasaki disease and receipt of immunoglobulin
in the ICD-9 þ IVIG set. If two admissions were within 30
days, they were regarded as being in the same acute stage. If
two admissions of the same patient were separated by more
than 30 days, they were regarded as two episodes of Kawasaki
disease in acute stages.
Patients' sex, age, and date of admission were retrieved. The
annual incidence, monthly distribution of patients, sex distri-
bution, recurrence rate, and complication rate were calculated.
The population statistics were obtained from the website of the
Ministry of the Interior, Taiwan.
According to the NHIRD, data that could be used to
identify patients or care providers, including medical in-
stitutions and physicians, are scrambled before being sent to
the National Health Research Institutes for database con-
struction and are further scrambled before being released to
individual researchers (http://w3.nhri.org.tw/nhird//en/Data_
Protection.html). A written agreement declaring there would
be no attempt to obtain information that could potentially
violate the privacy of patients or care providers was signed
before the beginning of data retrieval. This analysis was
conducted for research purposes only. There is no potential
conflict of interest. The computer-processed personal data
protection law and related regulations of the Bureau of NHI
and the National Health Research Institutes of Taiwan were
strictly followed. The protocol was reviewed and approved by
the National Health Research Institutes prior to data release.
The study protocol has also been approved by the institutional
review board of Taichung Veterans General Hospital.
SAS 9.1 for Windows (SAS Institute, Inc., Cary, NC, USA)
was used for data retrieval and data analysis. Chi-square tests
were applied for categorical data comparisons. The Poisson
regression model was used for comparing incidences. A p
value of <0.05 was considered statistically significant.
3. Results3.1. Annual incidences per 100,000 children aged under
5 years and sex distributionsThe demographic data are summarized in Table 2. The
annual incidence rates per 100,000 children <5 years old are
shown in Table 3. When we calculated the number of patients
with the ICD-9 code alone, the incidences ranged from 48.5 to
82.8 per 100,000 children <5 years of age. The average
incidence from 1997 to 2010 was 74.9 per 100,000 children
under 5 years of age. When we calculated the number of pa-
tients treated with IVIG, the incidences ranged from 21.5 to
68.5 per 100,000 children. The average incidence from 1997
to 2010 was 49.1 per 100,000 children under 5 years of age.
There were significant discrepancies between these two sets of
data. The difference was more significant in 2003, when a
severe acute respiratory syndrome (SARS) outbreak occurred
in Taiwan. The incidences declined significantly during the
Table 2
Demographic data for study cohort.
ICD-9 ICD-9 þ IVIG
Patient numbers 13179 8270
Sex a
Male 8223 (62.5%) 5142 (62.3%)
Female 4933 (37.5%) 3116 (37.7%)
Age group **
0e1 y 4670 (35.4%) 3210 (38.8%)
1e2 y 3551 (26.9%) 2317 (28.0%)
2e3 y 1867 (14.2%) 1240 (15.0%)
3e4 y 1034 (7.8%) 606 (7.3%)
4e5 y 706 (5.4%) 389 (4.7%)
Coronary aneurysms 894 (6.8%) 599 (7.2%)
** p < 0.001.
ICD-9 ¼ International Classification of Diseases, Ninth Revision;
IVIG ¼ intravenous immunoglobulin.
a Data were missing for 23 cases in the ICD-9 group and 12 in the ICD-
9 þ IVIG group.
Table 4
Monthly distribution of Kawasaki disease patients (all ages) using the ICD-9
data alone or the ICD-9 þ IVIG data.*
Month Patient number
ICD-9 ICD-9 þ IVIG
January 766 485
February 818 539
March 1036 691
April 1081 745
May 1186 782
June 1186 811
July 1123 677
August 1046 679
September 1015 661
October 969 632
November 841 565
December 761 495
* p ¼ 0.41 for February, July, and August.
ICD-9 ¼ International Classification of Diseases, Ninth Revision;
IVIG ¼ intravenous immunoglobulin.
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number of patients by using ICD-9 þ IVIG. There were no
major differences in sex distribution between these two sets of
data. The male-to-female ratio was around 1.7.3.2. Monthly distribution of patientsPatient distributions by months are summarized in Table 4.
In calculation of the distribution using the ICD-9 alone, the
peak months were MayeJuly. However, in calculation of the
distribution using both ICD-9 and IVIG, the peak months were
AprileJune. The discrepancy between the two methods was
greater during the summer vacation period (July and August).
If only children older than 5 years of age were analyzed, the
peak months were February, July, and August in the ICD-9 set.
These 3 months are winter and summer vacations in Taiwan.Table 3
Annual incidence of Kawasaki disease in Taiwan (per 100,000 children <5
years of age) using the ICD-9 data alone or the ICD-9 þ IVIG data.
Year Population
under 5 y
ICD-9 a ICD-9 þ IVIG a
Cases Incidence Cases Incidence
1997 1,599,094 775 48.46 344 21.51
1998 1,545,889 1019 65.92 583 37.71
1999 1,507,221 939 62.30 659 43.72
2000 1,489,242 949 63.72 637 42.77
2001 1,426,759 988 69.25 726 50.88
2002 1,350,829 879 65.07 381 28.20
2003 1,309,903 754 57.56 307 23.44
2004 1,243,939 815 65.52 438 35.21
2005 1,144,355 824 72.01 496 43.34
2006 1,092,942 821 75.12 683 62.49
2007 1,052,585 742 70.49 598 56.81
2008 1,026,206 808 78.74 662 64.51
2009 1,002,160 707 70.55 581 57.97
2010 964,093 798 82.77 660 68.46
ICD-9 ¼ International Classification of Diseases, Ninth Revision;
IVIG ¼ intravenous immunoglobulin.
a Statistically significant difference between two methods of estimating
incidence by Poisson regression model.However, in the ICD0 þ IVIG set, these two peaks were not
seen (Table 5).3.3. Recurrence rateWhen ICD-9 alone was used as the indicator of Kawasaki
disease, about 5.52% of patients had more than one episode of
this disease. However, when both ICD-9 and IVIG were used
as indicators, only 1.16% of patients had more than one
episode. The distribution of recurrent episodes is summarized
in Table 6. The cumulative recurrence rates estimated by two
definitions are depicted in Fig. 1. The 5-year recurrence rate
calculated by the KaplaneMeier method was 1.1% for the
ICD-9 þ IVIG set and 4.5% for the ICD-9 set. The median
recurrence time was about 401 days for the ICD-9 þ IVIG set
and 313 days for the ICD-9 set.Table 5
Monthly distribution of Kawasaki disease patients using the ICD-9 data alone
or the ICD-9 þ IVIG data for children older than 5 years of age.*
Month Patient number
ICD-9 ICD-9 þ IVIG
January 97 38
February 142 61
March 113 51
April 111 43
May 134 59
June 99 38
July 159 43
August 140 35
September 102 47
October 95 33
November 85 29
December 74 31
* p ¼ 0.040 for February, July, and August.
ICD-9 ¼ International Classification of Diseases, Ninth Revision;
IVIG ¼ intravenous immunoglobulin.
Table 6
Number of recurrent episodes per patient number using the ICD-9 data alone
or the ICD-9 þ IVIG data.
ICD-9 ICD-9 þ IVIG
Episode Patient number % Episode Patient number %
1 12,452 94.48 1 8174 98.84
2 476 3.61 2 87 1.05
3 150 1.14 3 4 0.05
4 53 0.4 4 1 0.01
5 24 0.18 5 1 0.01
6 12 0.09 6 1 0.01
7 5 0.04 7 1 0.01
8 4 0.03 8 1 0.01
9 2 0.02 9 0 0
10 1 0.01 10 0 0
ICD-9 ¼ International Classification of Diseases, Ninth Revision;
IVIG ¼ intravenous immunoglobulin.
Fig. 2. Proportions of patients with coronary aneurysm in different age groups,
using the ICD-9 data alone or the ICD-9 þ IVIG data. ICD-9 ¼ International
Classification of Diseases, Ninth Revision; IVIG ¼ intravenous
immunoglobulin.
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ageThe complication (coronary aneurysm) rates calculated by
both methods in different age groups are summarized in Fig. 2.
The average complication rate was 6.78% when calculated by
using ICD-9 alone. However, the average rate was 7.24%
when calculated using the ICD-9 þ IVIG. As shown in Fig. 2,
the complication rate was as high as 30% in older children
using the ICD-9 alone. However, there were almost no patients
older than 9 years with an aneurysm when ICD-9 þ IVIG were
used. This may reflect that patients who were admitted for a
survey later in life were regarded as incidence cases if we used
ICD-9 alone to identify Kawasaki disease in acute stages.
4. Discussion
In this study, we used a specific therapy, IVIG, as the in-
dicator of Kawasaki disease in acute stages and tried to
reanalyze the epidemiologic features of this disease in Taiwan.
The annual incidences of Kawasaki disease, which ranged
from 21.5 to 68.5 per 100,000 person-years for children underFig. 1. Cumulative recurrence rates of Kawasaki disease calculated by
different case definitions. ICD-9 ¼ International Classification of Diseases,
Ninth Revision; IVIG ¼ intravenous immunoglobulin.5 years, were lower than previously reported data obtained
using the NHIRD.6,19 Previous reports using only ICD-9
coding to analyze claims data were subject to overestimation
of the incidence of acute stages because physicians might code
Kawasaki disease as the main diagnosis when patients had not
been admitted for acute stages, for example, in case of
admission for angiography, computed tomography, or coro-
nary intervention. Moreover, because Kawasaki disease is
regarded as a life-long catastrophic disease under the NHI
scheme of Taiwan, physicians have to code Kawasaki disease
as the main diagnosis for their patients to eliminate copay-
ments when those patients are admitted due to other diseases
such as enterocolitis or pneumonia.
The average incidence with IVIG therapy was 49.1 per
100,000 person-years for children under 5 years, and it was
slightly higher than the incidence in Hong Kong (39) and
similar to that in Beijing (40.9e55.1).2,8 From a geographic
perspective, Japan and Korea have the highest and second
highest incidences in the world, 239.6 and 105.0, respec-
tively.9,10,13 Taiwan is geographically near to Hong Kong.
Moreover, most people in Taiwan are descendants of Chinese
people. Therefore, the incidence in Taiwan should be similar
to that in China. Hence, from both a geographic and a genetic
viewpoint, the results of our study are feasible. Some might
argue that this method might underestimate the incidence of
Kawasaki disease because there must be some patients who
were diagnosed late and not given IVIG. However, Kawasaki
disease is regarded as a catastrophic disease by the Bureau of
NHI, and the cost of IVIG is covered. Pediatricians in Taiwan
are familiar with Kawasaki disease. Therefore, we do not think
that many patients were misdiagnosed, as we show in Table 3.
Furthermore, if a patient was afebrile at the time of diagnosis,
there was no indication for admission.
The seasonal clustering of Kawasaki disease in acute stages
in our study was different from that of previous reports when
IVIG therapy was used as the indicator. Two previous reports
claimed that Taiwan had the most patients in summer.6,19 This
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they were not admitted for Kawasaki disease in acute stages.
Our results revealed that the peak season in Taiwan was late
spring to early summer (AprileJune). Spring is warm and
humid in Taiwan, which facilitates the transmission of
airborne infectious diseases. Moreover, our study showed that
the incidence declined when the SARS outbreak occurred in
2003. Huang et al's6 study failed to take this phenomenon into
account. At the time of SARS outbreak, people, including
young children and infants, were confined to their houses and
came in contact with others less often. As a result, trans-
mission of viral illness among young children might have been
reduced. This provides some support to one hypothesis about
the pathogenesis of Kawasaki disease, which states that Ka-
wasaki disease is an immune reaction caused by some kinds of
infectious agents.1,15,24 Our results using IVIG as the indicator
are similar to those found in reports from Hong Kong and
Beijing and somewhat different from those found in reports
from Japan and Korea.2,8e10 We believe that our results are
more reasonable from both a geographic and a genetic
perspective, as we mentioned above. When we counted only
children older than 5 years of age, we found that the number of
patients was highest in February, July, and August. These 3
months are winter and summer vacations in Taiwan. This
finding might suggest that some children with a past history of
Kawasaki disease were admitted for survey during their va-
cations. This phenomenon might have influenced the results of
previous reports (Tables 4 and 5).6,19
When we used ICD-9 alone as the indicator, the recurrence
rate was 5.52%. It was higher than that of a previous report by
Huang et al6 (1.5%). We believe that the discrepancy is caused
by the shorter study period (2003e2006) of their report.
Therefore, a certain number of patients were censored. How-
ever, the recurrence rate was 1.16% when we used IVIG as the
indicator. In comparison with Japan (3%), the recurrence rate
was significantly lower in Taiwan.10 The lower incidence of
Kawasaki disease in Taiwan might contribute to the lower
recurrence rate. These discrepancies also reflect a possible
fallacy in the methodology of previous studies. As physicians
code Kawasaki disease as the main diagnosis to receive
reimbursement for catastrophic disease from the Bureau of
NHI and avoid peer review, the recurrence rate should have
been overestimated in previous reports.6,19 Table 6 shows that
251 patients (1.9%) had more than two episodes of Kawasaki
disease in the ICD-9 set. Kawasaki disease usually recurs only
once.10 On the contrary, if we use IVIG as the indicator, only
nine patients (0.1%) had more than two episodes. We believe
that the patients who had more than five episodes were out-
liers. However, we do not think that the estimation of recur-
rence rate would not be influenced significantly using IVIG as
an indicator.
Huang et al6 reported that the development of coronary
aneurysms was associated with older age. When we used IVIG
as the indicator of acute stages, this association disappeared.
This reflected another possible fallacy in the methodology of
previous studies. Children with a past history of Kawasakidisease and coronary aneurysms could be included in a survey
when they reached school age, but that does not mean that they
should be regarded as acute cases. Although older age has
been reported to be a risk factor for coronary aneurysm in the
United States,14 we do not believe that this association exists
in Taiwan. Some might argue that the diagnosis of older
children might be delayed and hence the timing of IVIG
administration might be missed. However, it is hard to believe
that all the patients older than 9 years were misdiagnosed and
not given IVIG. Previous reports from Taiwan noted that older
age, being a risk factor for complications, might actually
reflect some patients who were readmitted for survey, and the
disease in not for acute stages.6,19 The coronary aneurysm
rates could be underestimated because the aneurysms could
develop later, after discharge from hospital. However, in order
to compare with previous reports,6,19 we adopted only the
diagnosis codes at admission.
This study used data from the NHIRD, which includes
almost the entire children population of Taiwan.22,23 We
believe that it offers an accurate evaluation of the incidence
and epidemiological features of Kawasaki disease in the study
period. However, this study has some limitations. First, pa-
tients' ID numbers were scrambled before being released to
individual researchers, so it is almost impossible to test the
validity of the results at the individual level. Second, the
severity of aneurysm could not be identified by the diagnosis
codes alone. Therefore, we do not know whether the aneurysm
was transient or persistent after the acute stages. Third, labo-
ratory test results were not included in the claims data. As a
result, we could not analyze the association between labora-
tory data and disease severity.
In conclusion, using different case definitions in claims data
analysis led to discrepancies. Previous reports might over-
estimate the incidence, recurrence rate, and complication rate
in older children. The new method might slightly underesti-
mate these parameters. The true incidence might lie in be-
tween these two methods.
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